emicizumab sold brand name hemlibra humanized bispecific monoclonal antibody treatment haemophilia developed genentech chugai subsidiary hoffmannla phase clinical trial found well tolerated healthy november approved united states treatment haemophilia developed resistance subsequently approved us fda april breakthrough therapy designation treatment haemophila developed resistance us food drug administration fda considers firstinclass common adverse reactions incidence injection site reactions headache emicizumab binds activated coagulation factor ix factor x mediating activation latter normally function coagulation factor viii missing haemophilia monoclonal article stub help wikipedia expanding drug article relating blood blood forming organs stub help wikipedia expanding httpsenwikipediaorgwikiemicizumab